Inactive Instrument

Cytori Therapeutics Inc Nasdaq

Equities

US23283K2042

Biotechnology & Medical Research

Cytori Therapeutics : To Acquire Azaya Therapeutics

January 19, 2017 at 12:06 pm

Azaya Therapeuti cs

President

Rat onale Key Terms

•

Promising Expanded Late-Stage Pipeline

The new Cytori Therapeutics combined pipeline will feature promising regenerative medicine therapies and two new oncology drugs for the treatment of large and underserved patient populations.

I NDICATION THERAPEUTI C AGENT STATUS

Hand Dysfunction in Scleroderma

2° Raynaud's Syndrome

,1,., -

Habeo.

Cell Therapy

PRE-CLINICAL PHASE 1/11 PHASE Ill MARKET APPROVAL

Knee Osteoarthritis ECCO-SO .&

Male Urinary Incontinence Breast Reconstruction

ECCi-SO @

DCCT-10 .&

Cutaneous Radiation

& Thermal Injury

Multiple Oncologic

ATl-1123

Indications LiposomalDocetaxel

Breast Cancer, Multiple Myeloma, Kaposi's Sarcoma, Ovarian Cancer

ATl-0918

Generic Liposomal Doxorubicin

PRECLINICAL BE STUDY MARKET APPROVAL

Cytori Therapeutics Inc. published this content on 19 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 January 2017 12:06:04 UTC.

Original documenthttp://ir.cytori.com/files/doc_presentations/2017/SS_CytoriAzaya_Factsheet_011817_v7.pdf

Public permalinkhttp://www.publicnow.com/view/1865FF1E333E6F9720320C54DC6BAF1DA8EFBA0D

Latest news about Cytori Therapeutics Inc

Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024	06-07	CI
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	06-07	MT
Plus Therapeutics, Inc. Draws $3.3 Million on Its Existing Margin Loan Facility with Pershing Llc	06-04	CI
Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	05-15
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Transcript : Plus Therapeutics, Inc. - Special Call	05-09
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	05-08	CI
Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	05-08	CI
Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC	05-04	CI
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	04-22	MT
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	04-22	CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	03-25	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	03-11	CI
Transcript : Plus Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
Transcript : Plus Therapeutics, Inc. - Special Call	11-20
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	11-20	CI
Top Premarket Gainers	11-03	MT
Plus Therapeutics Shares Jump Premarket on FDA Orphan Designation	11-03	DJ
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	31/10/23	CI
Transcript : Plus Therapeutics, Inc., Q3 2023 Earnings Call, Oct 31, 2023	31/10/23
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	31/10/23	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31/10/23	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	30/10/23	CI

Chart Cytori Therapeutics Inc

Duration

Period

More charts

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	47.96B
IQVIA HOLDINGS INC.	+0.69%	42.45B
LONZA GROUP AG	+44.70%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research